Your browser doesn't support javascript.
loading
Factors associated with variability in skeletal muscle radiodensity in patients with metastatic cancer.
Calixto-Lima, Larissa; Wiegert, Emanuelly Varea Maria; de Oliveira, Livia Costa; Chaves, Gabriela Villaça; Avesani, Carla Maria; Bezerra, Flavia Fioruci.
Afiliação
  • Calixto-Lima L; National Cancer Institute (INCA), Rio de Janeiro, RJ, Brazil. Electronic address: larissa_calixto@hotmail.com.
  • Wiegert EVM; National Cancer Institute (INCA), Rio de Janeiro, RJ, Brazil.
  • de Oliveira LC; National Cancer Institute (INCA), Rio de Janeiro, RJ, Brazil.
  • Chaves GV; National Cancer Institute (INCA), Rio de Janeiro, RJ, Brazil.
  • Avesani CM; Nutrition Institute, Rio de Janeiro State University, Rio de Janeiro, Brazil; Division of Renal Medicine and Baxter Novum, Department of Clinical Science, Technology and Intervention, Karolinska Institute, Stockholm, Sweden.
  • Bezerra FF; Nutrition Institute, Rio de Janeiro State University, Rio de Janeiro, Brazil.
Nutrition ; 120: 112351, 2024 Apr.
Article em En | MEDLINE | ID: mdl-38330891
ABSTRACT

OBJECTIVES:

This study aimed to explore factors associated with skeletal muscle radiodensity (SMD) variability in patients with metastatic cancer.

METHODS:

This study included 393 patients (median age 61 y, 70% women) who had computed tomography (CT) scans within 30 days of inclusion in the study. SMD was evaluated from CT by averaging the Hounsfield unit value of the total muscle area. Skeletal muscle index (SMI), visceral adipose tissue index (VATI), subcutaneous adipose tissue index (SATI), and total adipose tissue index (TATI) were also assessed by CT. Additionally, age, sex, race/skin color, disease characteristics, comorbidities, inflammatory markers, handgrip strength (HGS), and body mass index (BMI) were recorded and evaluated in the linear regression analysis to identify factors associated with SMD variability.

RESULTS:

Multivariate explanatory models having SMD as an independent variable were performed and included BMI (model 1, r2 = 0.699), TATI (model 2, r2 = 0.712) or VATI and SATI (model 3, r2 = 0.706) in addition to age, race/skin color, tumor site, kidney disease, serum albumin, HGS, and SMI as dependent variables. For all models, lower SMD was associated with higher age, BMI, and adiposity measurements, kidney disease, White race/skin color, and lower serum albumin, HGS, and SMI. The primary tumor site also contributed to changes in SMD in all models, specifically those located in the gastrointestinal tract, gynecologic, and bone and connective tissue.

CONCLUSION:

In this group of patients with metastatic cancer, lower SMD was associated with older age, White race/skin color, and an overall worse clinical condition.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Sarcopenia / Nefropatias / Neoplasias Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Sarcopenia / Nefropatias / Neoplasias Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2024 Tipo de documento: Article